SS Innovations' SSi Mantra Hits 15,000 Procedures as Texas Weighs Robotic Surgery Expansion

By The Building Texas Show•
SS Innovations' SSi Mantra surgical robot has surpassed 15,000 procedures and 200 telesurgeries, with 66% revenue growth and U.S. regulatory progress that could bring the platform to Texas healthcare providers.

Found this article helpful?

Share it with your network and spread the knowledge!

SS Innovations' SSi Mantra Hits 15,000 Procedures as Texas Weighs Robotic Surgery Expansion

SS Innovations International (NASDAQ: SSII), developer of the SSi Mantra surgical robotic platform, has passed 15,000 procedures performed with its systems, including roughly 750 cardiac surgeries, CEO Dr. Sudhir Srivastava said in an interview with The Motley Fool's Rachel Warren. The company has also completed more than 200 telesurgeries on the platform, 27 of them cardiac, as it works to extend specialist surgical expertise to underserved communities. The disclosure, first reported through NEWMEDIAWIRE, frames a growth story with potential consequences for Texas, where hospital systems, ambulatory surgery centers and rural providers continue to weigh capital investments in robotic-assisted care.

Srivastava pointed to the SSi Mantra's engineering as the commercial driver: 4K 3D visualization, a surgeon-controlled anatomical imaging capability and a modular design supporting up to five robotic arms. He attributed adoption to a combination of technological capability, clinical experience and affordability. That last factor matters in Texas, where independent surgery centers and regional hospitals often cite system cost and service contracts as barriers to entering robotic surgery. A lower-cost, modular platform could widen the field of providers able to offer minimally invasive procedures, though SS Innovations has not announced Texas-specific deployments in the source material.

The company is preparing to expand its Indian manufacturing capacity through a planned 10-acre facility, aiming to bring more production capabilities in-house. Regulatory applications in Europe and the United States are also progressing, with management targeting international expansion through direct sales and opportunities in ambulatory surgery centers. For Texas, the U.S. regulatory track is the central variable: clearance would place the SSi Mantra in competition with established robotic surgery incumbents and give Texas surgery centers another option as they plan capital spending. Details of the company's strategy are available in the interview summary and through Read More coverage.

Commercial momentum is measurable. First-half 2026 revenue rose approximately 66% year-over-year to about $25 million, according to the source. That growth rate suggests the platform is moving beyond early adoption, and it gives the company resources to pursue the regulatory and manufacturing expansion it has outlined. Telesurgery, meanwhile, carries longer-range implications for Texas: a state with large rural regions and specialist shortages could use remote surgical support to connect smaller facilities with experienced surgeons, provided connectivity, licensure and clinical protocols align. The company has framed telesurgery as a way to extend specialist expertise to underserved communities, and the 200-plus procedures completed offer an early signal of feasibility.

Forward-looking statements in the source carry customary risks, and the company notes that actual results may differ materially. Still, the combination of procedure volume, revenue growth and pending U.S. regulatory progress makes SS Innovations a company worth watching for Texas healthcare employers, medical device suppliers and workforce training programs. Additional company updates are available through the SSII newsroom.